Biota

November 2012

• "One of the top ten projects in infectious diseases to watch in 2012:  BTA-C286 RSV antiviral", presented by Ms Joy Hewitt, Director, Business Development.
  29-30 November 2012:  Windhover Therapeutic Area Partnership conference, Boston, USA.

September 2012

• "In Vitro  and In Vivo Biology of Benzothiazole Urea-Based, Dual-Targeting DNA Supercoiling Inhibitors for the Treatment of Bacterial Infections", presented by Dr James Palmer, Director, Drug Discovery.
  9-12 September 2012: 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2012), San Francisco,  USA. 
• "Discovery of a New Series of Pan-genotypic NS5b Inhibitors for Hepatitis C: the Indazole Amide Class of Site IV Polymerase Antivirals", presented by Dr Alistair Draffan, Director, Drug Discovery. 
  9-12 September 2012: 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2012), San Francisco,  USA. 
  and 14-16 September 2012: EASL-AASLD joint conference on the therapy of hepatitis C: clinical application and drug development, Prague, Czech Republic

April 2012

• "Dual-Targeting DNA Supercoiling Inhibitors for the Treatment of Bacterial Infections", presented by Dr Jim Palmer, Director, Drug Discovery.
  17-18 April 2012: The Challenges of Antibacterial Drug Development (Drug Discovery Chemistry), San Diego, USA.
• "Synthesis, in vitro, and in vivo biology of dual-targeting DNA supercoiling inhibitors for the treatment of bacterial infections", presented by Dr James Palmer, Director, Drug Discovery.
  15-20 April 2012: New Antibacterial Discovery and Development (Gordon Research Conferences), Lucca, Italy.
• "Optimising Small-Molecule Inhibitors of FtsZ for Improved Potency, Efficacy and Drug-Like Properties", presented by Neil Stokes, Associate Director, Research.
  15-20 April 2012: New Antibacterial Discovery and Development (Gordon Research Conferences), Lucca, Italy.

February 2012

• "An Orally Available 3-Ethoxybenzisoxazole Capsid Binder with Clinical Activity against Human Rhinovirus", authored by Stephanie Hamilton, Bo Lin, Angela Luttick, Michael Parker, Jane Ryan, Simon Tucker, Craig Morton.
  February 2012:  For ACS Med. Chem. Lett. 2012 Vol 3 pp303-307.
• "Early stage drug discovery in the Biota Structural Biology Laboratory and the ACRF Rational Drug Discovery Centre".
  Authors: Tracy Nero, Jessica Holien and Michael Parker. Presented by Dr Craig Morton, Principal Research Scientist, Drug Target Discovery.
  5-9 February 2012: Lorne Protein Conference, Lorne, Melbourne, Australia.

December 2011

• "Discovery of new orally active antivirals for the treatment of Respiratory Syncytial Virus (RSV) identification of a clinical candidate", presented by Dr Kelly Anderson, Research Scientist, Drug Discovery.
  6 December 2011: Biomolecular at the Beach, Torquay, Melbourne, Australia.

November 2011

• "Don't divide, and conquer: FtsZ inhibitors as antibiotics". Plenary presentation by Dr Simon Tucker, Vice President, Research.
  8-11 November 2011: University of Queensland Institute for Molecular Bioscience Symposium - Brisbane.

October 2011

• "IP Reform in Australia: A health and status check", presented by Dr Kristy McCamley, Intellectual Property Manager & Patent Attorney. 
  16-19 October 2011:  Ausbiotech National Conference, Adelaide, Australia.
• "The discovery and development of the next generation influenza neuraminidase inhibitors:  long-acting neuraminidase inhibitors for once-only treatment of influenza".  Authors: the Daiichi Sankyo and Biota long-acting neuraminidase inhibitor R&D teams.  Plenary presentation by Dr Simon Tucker, Vice President, Research.
  6-7 October 2011:  7^th Australian Influenza Symposium, Melbourne, Australia.
• "Amiloride is a competitive inhibitor of coxsackievirus B3 RNA polymerase", published by Gazina, E., Smidansky, E., Holien, J.H., Harrison, D., Cromer, B.A., Arnold, J., Parker, M.W., Cameron, C. & Petrou, S.
  October 2011:  J. Virol., Vol 85, pp 10364-10374.

September 2011

• "Membrane proteins: a toxic choice", presented by Prof Michael Parker, Head of Laboratory (Consultant), Structural Biology Laboratory.
  September 2011:  Australian Society for Biochemistry and Molecular Biology Annual Conference (ComBio2011), Cairns, Queensland, Australia.
• "BTA798 is an Orally Bioavailable and Potent inhibitor of Human Rhinovirus Both in vitro and in an Experimental Challenge Virus Infection Model in Healthy Volunteers", presented by Dr John Lambert, Vice President Product Development Operations.
  19 September 2011: 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, USA.